Eli Lilly has revealed the fourth new manufacturing site in its $27 billion capital investment spree in the US – a $3.5 billion facility in Lehigh Valley, Pennsylvania. The company said the site will ...

Matchpoint Therapeutics is preparing to take its oral T cell modulator through proof-of-concept clinical testing in ...

As it waits for an FDA decision on one non-opioid pain drug, Viatris has its eye on two more, via a takeover bid for Pacira ...

US pharma trade organisation PhRMA is challenging the Trump administration's GLOBE model for Most-Favoured Nation (MFN) ...

Exclusive analysis for World Health Expo (WHX) by Frost & Sullivan forecasts precision medicine growth of more than 10% in ...

Raising funding, assembling the initial team, building lab operations from the ground up, generating proof-of-concept ...

MSD has been rocked by a court judgment ordering it to stop manufacturing and selling its subcutaneous formulation of cancer ...

Pfizer acquired Tukysa as part of its $43 billion takeover of Seagen in 2023, three years after the drug first reached the US ...

The Nobel Prize in Chemistry 2026 has been awarded to two scientists - Henri B Kagan and Kensō Soai – for discoveries on ...

Just months after launching an open-source 'virtual biology' platform, non-profit research organisation Biohub has raised ...

Wegovy has since been joined in the UK market by Eli Lilly's oral GLP-1 agonist Foundayo (orforglipron), which was approved by the MHRA in August. Neither product is covered by the NHS, but can be ...

Novartis has a much-anticipated approval for its spinal muscular atrophy (SMA) treatment onasemnogene abeparvovec in the US, getting a green light for a new version that can make more patients ...